$1.12
+0.34 (+44.11%)
Open$0.75
Previous Close$0.78
Day High$1.14
Day Low$0.75
52W High$2.44
52W Low$0.57
Volume—
Avg Volume34.2K
Market Cap30.18M
P/E Ratio—
EPS$-0.16
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,828.6% upside
Current
$1.12
$1.12
Target
$44.00
$44.00
$29.80
$44.00 avg
$55.04
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.74M | 5.58M | 6.05M |
| Net Income | 1.11M | 1.28M | 1.11M |
| Profit Margin | 19.3% | 22.9% | 18.3% |
| EBITDA | 2.54M | 2.28M | 2.52M |
| Free Cash Flow | 874.9K | 1.03M | 1.03M |
| Rev Growth | +19.1% | +13.5% | +5.7% |
| Debt/Equity | 1.60 | 1.67 | 1.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |